Find out which choices have the greatest impact on scalability, cost, and manufacturing risk.
Many cell and gene therapy programs encounter their biggest manufacturing challenges not at launch, but during the transition from clinical to commercial scale.
Early development decisions, from process design to technology selection, can have lasting effects on scalability, cost, and overall manufacturing risk. Learn which decisions deserve the most attention before scale-up begins.
